• Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic.
• Clinical and immune activity of Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting, postponed to August 2020.
BERKELEY, Calif., and VANCOUVER, British Columbia, March 26, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announce that the Phase I/IIa clinical study of Bria-IMT™ with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012 is ongoing and recruiting patients amidst the COVID-19 pandemic. In fact, BriaCell has enrolled a new patient in the study this week.
“We are determined to provide safe and effective treatments for advanced breast cancer patients with no effective treatment options. Our experts believe that our novel immunotherapy may work additively or synergistically with checkpoint inhibitors to boost the body’s immune response to cancer cells and we are firmly committed to continuing our scientific and clinical advancements,” said Dr. Bill Williams, BriaCell’s President & CEO.
“BriaCell’s clinical trial is ongoing throughout the COVID-19 pandemic. We are confident that the participating clinical sites in BriaCell’s clinical trial are fully compliant with state-specific regulations, and will take every appropriate measure to meet and exceed safety standards for their patients amid the COVID-19 pandemic.”
BriaCell also has an abstract accepted for a poster presentation at the American Association of Cancer Research (AACR) meeting, which is typically held in April each year. This year the COVID-19 pandemic has caused the meeting to be postponed to August 2020. For more information go to https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/.
The AACR was founded in Washington, D.C., May 7, 1907, by a group of 11 physicians and scientists intending “to further the investigation and spread the knowledge of cancer.” To prevent and cure cancer using research, education, communication, collaboration, funding and advocacy has been the mission of AACR. With its programs and services, AACR advances research in cancer and related biomedical science by facilitating exchange of knowledge and innovations among scientists and clinicians dedicated to the fight against cancer, providing education and training in oncology treatment and advancing cancer etiology, prevention, early detection, diagnosis and treatment worldwide.
For more information on AACR, please visit: https://www.aacr.org.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
For additional information on BriaCell, please visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation (also known as “forward-looking statements”) which are subject to known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at www.sedar.com.
These forward-looking statements include, but are not limited to, BriaCell’s plans, objectives, expectations and intentions. Such forward-looking statements reflect BriaCell’s current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this news release are based upon what BriaCell believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
BriaCell Therapeutics Corp.:
Manager, Corporate Development